Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Выпуски:
Том 40, 2020 Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2018027460
pages 433-451

IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction

Charles de Roquetaillade
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France
Guillaume Monneret
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Morgane Gossez
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Fabienne Venet
EA7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)", Université Claude Bernard Lyon 1, Lyon, France; Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France

Краткое описание

Sepsis, defined as life-threatening organ dysfunction caused by dysregulated host response to infection, has recently been acknowledged as a worldwide health priority. Sepsis remains the leading cause of mortality in intensive care units and accounts for 6 million deaths every year. Few therapeutic options targeting host immune response in sepsis have demonstrated their efficacy so far. Increasing evidence suggests that a profound immune suppression develops following sepsis, affecting innate and adaptive immune response, of which intensity and duration is associated with increased risk of death and nosocomial infection. Immunostimulant treatments are thus now evaluated in sepsis, and recombinant human IL-7 (rhIL-7) represents a promising candidate. rhIL-7 has been evaluated in several clinical trials in patients with altered lymphocytic responses (HIV infection, hematopoietic stem cell transplantation, and cancer). Recent studies in animal models and in patients' samples ex vivo demonstrated its efficacy in improving sepsis-induced T cell alterations. Finally, the first clinical trial evaluating rhIL-7 in septic shock patients has just been published. This review will discuss the use of rhIL-7 to treat sepsis-induced T cell dysfunction by introducing the pathophysiology of sepsis and sepsis-related lymphocyte alterations before focusing on rhIL-7 and its potential use of as a therapeutic intervention in patients.